Clinical Characteristics and Outcomes of Hypersensitivity Pneumonitis: A Population-Based Study in China
Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis, is an immune-mediated interstitial lung disease (ILD) triggered by repeated inhalation of environmental antigens. Despite its clinical significance, the epidemiology, clinical characteristics, and outcomes of HP remain understudied, particularly in China. This population-based study conducted at Nanjing Drum Tower Hospital aimed to elucidate the incidence, clinical features, and prognostic factors of HP, with a focus on differentiating acute (AHP) and chronic (CHP) forms. The study also developed a novel clinical scoring model to aid in diagnosing CHP, addressing a critical gap in clinical practice.
Incidence and Study Population
The retrospective cohort included 101 HP patients diagnosed among 4,289 new ILD cases admitted between 2009 and 2017, yielding an annual incidence of 2.4% (range: 1.3%–3.3%). Patients were classified into AHP (n=72) and CHP (n=29) groups based on updated international criteria, which emphasize clinical, radiological, and pathological distinctions. The categorization aligned with recent recommendations to simplify HP classification into acute/inflammatory and chronic/fibrotic phenotypes, eliminating the ambiguous subacute category.
Baseline Clinical Characteristics
Significant differences emerged between AHP and CHP groups. CHP patients were older (mean age: 57.8 vs. 51.9 years, P=0.029) and had a higher proportion of smokers (55.2% vs. 24.0%, P=0.004). Symptom duration was markedly longer in CHP (median: 12 vs. 2 months, P<0.001). Weight loss (31.0% vs. 1.4%), crackles (69.0% vs. 36.1%), digital clubbing (20.7% vs. 1.4%), and cyanosis (20.7% vs. 6.9%) were more prevalent in CHP (P<0.05). Fever, conversely, was more common in AHP (41.7% vs. 20.7%, P=0.046).
Radiological and Functional Findings
High-resolution computed tomography (HRCT) revealed distinct patterns:
- AHP: Predominant ground-glass opacities (GGOs, 98.6%), centrilobular nodules (94.4%), and air trapping/mosaic attenuation (73.6%).
- CHP: Fibrotic features, including reticular patterns (100%), traction bronchiectasis (55.2%), and honeycombing (37.9%) (P<0.001 for all).
Pulmonary function tests showed lower FEV1/FVC ratios in CHP (86.35% vs. 82.66%, P=0.035), suggesting obstructive tendencies, though total lung capacity (TLC) and diffusion capacity (DLCO) did not differ significantly.
The ADSUC Scoring System for CHP Diagnosis
To address diagnostic challenges in CHP, a clinical scoring system (ADSUC) was developed using five variables:
- Age (>55 years: 1 point)
- Duration of symptoms (>6 months: 1 point)
- Smoking history (present: 1 point)
- Unidentified antigen exposure (present: 1 point)
- Chest HRCT findings (reticular pattern, traction bronchiectasis, or honeycombing: 1 point each, up to 3 points).
The model demonstrated excellent diagnostic accuracy (AUC: 0.935, 95% CI: 0.883–0.987, P<0.001). A score ≥4 had a 100% positive predictive value for CHP, while a score ≤2 excluded CHP with 92.9% certainty. This tool offers a practical alternative to invasive biopsies, particularly in resource-limited settings.
Disease Progression and Risk Factors
Among AHP patients, 15.3% (n=11) progressed to CHP during follow-up. Multivariate analysis identified unidentified antigen exposure as the sole independent risk factor for progression (OR: 0.078, 95% CI: 0.007–0.864, P=0.038). This underscores the importance of antigen identification and avoidance in preventing chronicity.
Survival and Prognostic Determinants
Kaplan-Meier analysis revealed significantly worse survival in CHP (median survival time [MST]: 74.5 months) versus AHP (MST: 137.2 months, P=0.011). Additional poor prognostic factors included:
- Smoking history (P=0.001)
- Unidentified antigen exposure (P=0.005)
- Fibrosis on HRCT (P=0.011).
Cox regression confirmed unidentified exposure (HR: 0.117, 95% CI: 0.02–0.681, P=0.017) and low baseline TLC% (HR: 0.965, 95% CI: 0.937–0.993, P=0.017) as independent predictors of mortality. These findings highlight the interplay between antigen avoidance, pulmonary reserve, and disease outcomes.
Treatment Patterns
Corticosteroids were widely used (83.2% of patients), with higher utilization in CHP (96.6% vs. 77.8%, P=0.023). N-acetylcysteine (NAC) was also more common in CHP (93.1% vs. 54.2%, P<0.001), reflecting efforts to mitigate fibrosis. Immunosuppressants like cyclophosphamide and azathioprine were sparingly used, consistent with limited evidence for their efficacy in HP.
Discussion and Clinical Implications
This study provides the first comprehensive characterization of HP in a Chinese population. The 2.4% incidence aligns with global estimates but contrasts with higher rates in occupational cohorts, suggesting underdiagnosis or regional antigen variability. The ADSUC model addresses a critical need for non-invasive CHP diagnosis, particularly where histopathology is unavailable.
The strong association between unidentified antigens and progression to CHP emphasizes the need for standardized antigen screening protocols. Questionnaires targeting occupational, hobby-related, and environmental exposures could enhance detection. Similarly, smoking cessation programs may improve outcomes, given its link to fibrosis and mortality.
Limitations and Future Directions
The single-center, retrospective design and small CHP cohort limit generalizability. Histopathological confirmation was lacking in 23.8% of cases, though HRCT and BAL findings supported diagnoses. Prospective multicenter studies are needed to validate the ADSUC model and explore regional antigen profiles.
Conclusion
This study delineates the clinical and prognostic spectra of HP in China, reinforcing the importance of early antigen identification and smoking cessation. The ADSUC scoring system offers a robust tool for diagnosing CHP, while unidentified antigen exposure and reduced TLC% emerge as critical prognostic markers. These insights can guide risk stratification, therapeutic decisions, and patient counseling in HP management.
https://doi.org/10.1097/CM9.0000000000000256
Was this helpful?
0 / 0